Loqtorzi (toripalimab-tpzi: Inovio Pharmaceuticals, Coherus BioSciences) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Loqtorzi Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.

The Loqtorzi market is witnessing significant growth, driven by several factors. In the historic period, the rise in nasopharyngeal carcinoma (NPC) diagnosis rates in endemic regions, advancements in immunotherapy research, successful PD-1 blockade trials, increased oncology research funding, and the expansion of specialty cancer centers have fueled this growth.

Looking ahead, the forecast period will see momentum sustained by global immunotherapy drug approvals, rising investments in rare cancer treatments, and advancing oncology biologics access. The increasing use of combination immunotherapies and innovation in immune modulation therapies remain pivotal.

Trends include the adoption of PD-1 inhibitors in rare cancers, a concentrated focus on nasopharyngeal carcinoma, and growth in immuno-oncology pipelines. The expansion of immune checkpoint blockade therapies and augmented global clinical trial activity are notable. The increase in NPC prevalence, linked to factors such as Epstein-Barr virus exposure and genetic predispositions, is poised to drive Loqtorzi market growth.

Loqtorzi (toripalimab) offers a therapeutic edge by boosting immune defenses against NPC, through PD-1 pathway inhibition, enhancing treatment options for recurrent or metastatic NPC. A significant milestone is its October 2023 FDA approval for first-line RM-NPC treatment and solo use post-platinum-based chemotherapy failure. Market dynamics are further shaped by the focus on biosimilar development, offering affordable biological therapy alternatives. For example, Dr. Reddy's Laboratories launched a biosimilar in India, increasing accessibility.

Strategic collaborations continue to advance the market, exemplified by the partnership between Inovio Pharmaceuticals and Coherus BioSciences. This aims to leverage Loqtorzi's capabilities with INO-3112 for treating HPV16/18-positive oropharyngeal squamous cell carcinoma, advancing therapeutic outcomes. Leading market players include Coherus BioSciences Inc. and Shanghai Junshi Biosciences Co. Ltd.

Regionally, North America dominates the Loqtorzi market, with Asia-Pacific anticipated as the fastest-growing region in the near future. Tariffs impacting biologic raw materials and logistics are driving a shift towards localized manufacturing and distribution, particularly in Asia-Pacific and Europe. Still, they promote domestic manufacturing and regional clinical infrastructure.

The Loqtorzi market comprises sales of diagnostic kits, biomarker assays, companion diagnostics, drug delivery systems, and post-treatment care products. The market value reflects enterprise revenues from global sales activities across various channels, with diverse formulations primarily for intravenous administration.

Key Topics Covered:

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Loqtorzi Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Loqtorzi Market Attractiveness Scoring and Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment and Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Loqtorzi Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List of Key Raw Materials, Resources & Suppliers

3.3. List of Major Distributors and Channel Partners

3.4. List of Major End Users

4. Global Loqtorzi Market Trends and Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics and Precision Medicine

4.1.2 Artificial Intelligence and Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 and Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech and Circular Economy

4.2. Major Trends

4.2.1 Increasing Adoption of Pd-1 Inhibitors in Rare Cancers

4.2.2 Growing Focus on Nasopharyngeal Carcinoma Treatment

4.2.3 Expansion of Immuno-Oncology Pipelines

4.2.4 Rising Use of Immune Checkpoint Blockade Therapies

4.2.5 Enhanced Global Clinical Trial Activity

5. Loqtorzi Market Analysis of End Use Industries

5.1 Hospitals

5.2 Oncology Clinics

5.3 Specialty Cancer Centers

5.4 Research Institutions

5.5 Specialty Pharmacies

6. Loqtorzi Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, and Covid and Recovery on the Market

7. Global Loqtorzi Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis

7.1. Global Loqtorzi PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Loqtorzi Market Size, Comparisons and Growth Rate Analysis

7.3. Global Loqtorzi Historic Market Size and Growth, 2020-2025, Value ($ Billion)

7.4. Global Loqtorzi Forecast Market Size and Growth, 2025-2030, 2035F, Value ($ Billion)

8. Global Loqtorzi Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Loqtorzi Market Segmentation

9.1. Global Loqtorzi Market, Segmentation by Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Injectable Formulation (Intravenous), Lyophilized Powder for Reconstitution

9.2. Global Loqtorzi Market, Segmentation by Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Treatment of Small Cell Lung Cancer (SCLC), Treatment of Other Solid Tumors

9.3. Global Loqtorzi Market, Segmentation by Patient Demographics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Adult Patients, Geriatric Patients, Pediatric Patients

9.4. Global Loqtorzi Market, Segmentation by Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

9.5. Global Loqtorzi Market, Segmentation by End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Oncology Clinics, Specialty Pharmacies, Research Institutions

For more information about this report visit https://www.researchandmarkets.com/r/afj462

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.